Key result
DNJ5a improves mitochondrial health and cardiac function in rodent hypertrophy models by targeting OPA1.
Why the study?
Pathological cardiac hypertrophy often features myocardial mitochondrial dysfunction, making potent mitochondrial-targeting compounds potentially beneficial for elucidating mechanisms and treating patients.
Does DNJ5a ameliorate cardiac hypertrophy and improve mitochondrial health in preclinical models?
Population
Patient-specific cybrid cells, iPSC-derived cardiomyocytes, and mouse and rat cardiac hypertrophy models
Comparison
Novel DNJ derivatives vs DNJ or controls
Design
Preclinical in vitro and in vivo screening and mechanistic study
Authors
Loading...
Hypothesis-generating for OPA1 targeting in hypertrophy; leaves open clinical translation pending human studies.
Does DNJ5a ameliorate cardiac hypertrophy and improve mitochondrial health in preclinical models?
The novel DNJ derivative DNJ5a ameliorates cardiac hypertrophy in preclinical models by specifically targeting OPA1 to restore mitochondrial health.
Ding et al. (2025) studied this question. DNJ5a significantly improved mitochondrial health and cardiac function in rodent models of cardiac hypertrophy, targeting OPA1 to enhance therapeutic efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: